214665 Finsbury WWP pp29-pp36 6 15 09 1:27 PM Page 29 Finsbury Worldwide Pharmaceutical Trust PLC Annual Report 2009 29 Directors Remuneration Report The Board has prepared this report in accordance with the The fees for the Directors are determined within the limits set requirements of Schedule 7A to the Companies Act 1985 the out in the Companys Articles of Association, the maximum Regulations.
An ordinary resolution for the approval of this aggregate amount currently being 200,000.
Directors are not report will be put to the members at the forthcoming Annual eligible for bonuses, pension benefits, share options, long-term General Meeting.
incentive schemes or other benefits.
The policy is for the Chairman of the Board and Chairman of the Audit Committee The law requires the Companys auditors to audit certain of the to be paid higher fees than the other Directors to reflect their disclosures provided.
Where disclosures have been audited, more onerous roles and additional responsibilities.
they are indicated as such.
The Auditors opinion is included in their report on pages 31 and 32.
DIRECTORS SERVICE CONTRACTS It is the Boards policy that none of the Directors has a service REMUNERATION COMMITTEE contract.
The terms of their appointment provide that The Company has seven non-executive Directors, five of whom Directors shall retire and be subject to election at the first are considered by the Board to be independent.
The whole Annual General Meeting after their appointment and Board fulfils the function of the Remuneration Committee re-election at least every three years thereafter.
The terms also provided that a majority of the Directors present are provide that a Director may resign by notice in writing to the independent.
The Board may utilise the services of the Board at any time and may be removed without notice and Company Secretary or external advisers to provide advice that compensation will not be due on leaving office.
The when the Directors consider the level of Directors fees.
Companys policy is for the Directors to be remunerated in the The Directors fees are reviewed annually by the Remuneration form of fees payable quarterly in arrears, to the Director Committee: such review will not necessarily result in a change personally or to a specified third party.
In March 2009, the Remuneration Committee carried out a review of the level of Directors fees in relation YOUR COMPANYS PERFORMANCE both to fees paid to the boards of other investment trust The Regulations require a line graph be included in the companies and also to the Boards corporate governance Directors Remuneration Report comparing, for a period of five obligations.
The Board decided, on the advice of the years, on a cumulative basis, the total return assuming all Remuneration Committee, that the amounts should remain dividends are reinvested to shareholders and the total unchanged for the present.
shareholder return on a notional investment made up of shares of the same kind and number as those by reference to POLICY ON DIRECTORS FEES which the Datastream World Pharmaceutical and The Boards policy is that the remuneration of Directors should Biotechnology Index total return, sterling adjusted, chosen as reflect the experience of the Board as a whole, be fair and it is the Companys stated benchmark, is calculated.
comparable to that of other investment trusts that are similar in size, have a similar capital structure Ordinary shares, and have a similar investment objective.
It is intended that this policy will continue for the year ending 31 March 2010 and subsequent years.
214665 Finsbury WWP pp29-pp36 6 15 09 1:27 PM Page 30 Finsbury Worldwide Pharmaceutical Trust PLC Annual Report 2009 30 Directors Remuneration Report continued SHAREHOLDER TOTAL RETURN FOR THE FIVE YEARS TO 31 MARCH 2009 140 130 120 110 100 90 80 70 60 50 Mar Mar Mar Mar Mar Mar 04 05 06 07 08 09 Datastream Pharmaceutical and Biotechnology Index Finsbury Worldwide Share price total return total return, sterling adjusted Rebased to 100 as at 31 March 2004 Source: Fundamental Data & Thomson Datastream DIRECTORS EMOLUMENTS FOR THE YEAR AUDITED The Directors who served in the year received the following emoluments in the form of fees: Fees Fees 2009 2008 000 000 Martin Smith 27 8 Josephine Dixon 21 22 Paul Gaunt 19 20 Professor Duncan Geddes 19 20 Dr David Holbrook 19 8 Ian Ivory 930 James Noble 6 Samuel D Isaly 19 20 Anthony Townsend 19 19 152 153 Appointed to the Board on 8 November 2007 and became Chairman on 23 July 2008.
Retired from the Board on 23 July 2008.
Retired from the Board on 9 July 2007.
APPROVAL The Directors Remuneration Report on pages 29 and 30 was approved by the Board of Directors on 11 June 2009 and signed on its behalf by Martin Smith Chairman.
